Local reactions to the second dose of the  BNT162 COVID  ‐19 vaccine

descriptionPublicationkeyboard_double_arrow_right Article 01 Jun 2021 Italy English Publisher:WileyJournal:Dermatologic Therapy, volume 34 (issn: 1396-0296, eissn: 1529-8019,

Copyright policy )

Authors: Tammaro A.; Adebanjo G. A. R.; Parisella F. R.; De Marco G.; Rello J.;

doi: 10.1111/dth.15000

pmid: 34031953

pmc: PMC8209913

handle: 11573/1575542

Local reactions to the second dose of the BNT162 COVID ‐19 vaccine

- Summary
- Subjects
- Metrics

Abstract

Multiple strategies have been implemented worldwide to fight the burden of the pandemic caused by COVID-19, with vaccination being one of the most promising.1 Notably, the first vaccine to be authorized in Italy was the BNT162 mRNA-based vaccine, which has also been approved in the USA, United Kingdom, and Canada.1,2 As a matter of fact, RNA vaccines are immunogenic and cost-effective.1

Country

Italy

Related Organizations

View all View all

Keywords

2708 Dermatology, COVID-19 Vaccines, SARS-CoV-2, Vaccination, COVID-19, Humans, Dermatology, General Medicine, humans; SARS-CoV-2; vaccination; COVID-19; COVID-19 vaccines

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	5
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%